newsfilter
← Latest News
Business Wire·

Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Chronic Spontaneous Urticaria

- Trial did not meet the primary endpoint of mean change in Urticaria Activity Score over seven days (UAS7) at 12 weeks- Evommune to continue development of EVO756 in Atopic Dermatitis and MigraineEvommune, Inc.